Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.
Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.